Bioanalysis
Altasciences Completes Expansion of New State-Of-The-Art Laboratory in Columbia, Missouri
Laval, Québec, October 31, 2023 – Altasciences is pleased to announce the completion of its laboratory facilities in Columbia, MO.
The newly expanded, 8,000-square-foot space, which includes a test material department, features
state-of-the-art equipment and forty-eight workbenches, with a vast range of services, including ligand binding assays, flow cytometry, biomarker analysis, and cell culture capabilities.
“This laboratory expansion is a significant step forward in our ability to meet the increasing needs of sponsors. Our focus on growing our bioanalytical capabilities highlights Altasciences' mission to help develop potentially life-saving therapeutics, and get them to market faster,” said Marie-Hélène Raigneau, Co-chief Operating Officer, Altasciences. “Our integrated CRO/CDMO services combine bioanalytical services with preclinical and clinical study solutions, manufacturing services, and all complementary research support services, for maximum efficiency.”
This is Altasciences’ third purpose-built laboratory. Altasciences’ laboratory sciences has the scientific, regulatory, and operational expertise for quantitation of drugs and biomarkers from discovery to preclinical to Phase IV, using bioanalysis platforms including mass spectrometry, ligand binding assay, PCR, flow cytometry, ELISpot, and cell based assays in routine and specialized areas such as immunomodulation and cell and gene therapy. All three laboratories across North America are uniformly designed and managed.
Whether as a standalone bioanalytical service or as part of an integrated program, Altasciences provides top-quality data for TK, PK, and PD determinations to support preclinical and clinical studies.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit altasciences.com.
Retrospective Safety Evaluation of Tyrosine Kinase Inhibitor Products When Administered in Single Dose in Crossover Studies to Healthy Volunteers
Quantitation of Bemnifosbuvir and Metabolites in Human Bronchoalveolar Lavage by LC-MS/MS
PCR's Key Role in Therapeutic Advancements
Cell and gene therapies are revolutionizing medicine with personalized treatments; PCR analysis plays a crucial role in their development.
In this issue of The Altascientist:
- explore the different approaches and applications of qPCR and ddPCR analysis for nonclinical and clinical studies;
- discover the unique advantages they offer; and
- review two case studies demonstrating how these methods are shaping the future of gene therapy research.
Have questions? Speak to a scientist.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Sensitive Quantitation of Antisense Oligonucleotides Using Capitainer® qDBS Microsampling Device Coupled With Hybridization LC-MS/MS
All Things Oligonucleotides!
The therapeutic development of antisense oligonucleotides (ASOs) has expanded its reach to encompass diseases like Huntington's, Alzheimer's, and Parkinson's.
Given their ability to pinpoint disease pathogenesis's root cause, ASOs are a hopeful avenue for addressing stubborn illnesses and genetic disorders.
Explore our resource library to learn more about oligonucleotides and their potential, from synthesis techniques to innovative applications.
Poster Presentations:
Application of Mitra Microsampling for the Quantitative Bioanalysis of ASOs
Development of a Surrogate Cerebrospinal Fluid Matrix for Quantitative Analysis of ASOs by Hybridization LC-MS
Development of an Oligonucleotide Drug Immunogenicity Assay
eBook:
Bioanalytical Development for the Analysis of ASOs
Special Issue of The Altascientist:
Antisense Oligonucleotides (with two case studies!)
Research Articles:
Accurate Quantification of ASOs in Mouse Serum Using Microsampling LC-MS/MS
Altasciences has been recognized as a 2023 CRO Leadership Award Champion in the Capabilities category, as voted by you in ISR’s annual CRO Quality Benchmarking survey.
Altasciences' Facilities: Moving in Unison
Choosing the Best Bioanalytical Platform for Your Program
Choosing the right bioanalytical platform for your molecule’s intended use and program segment is crucial to obtaining reliable, robust data in a timely manner.
Microsampling for Pediatric Baricitinib Pharmacokinetics